Results 41 to 50 of about 299,239 (347)
Secondary Publication: COVID-19 Pandemic: Drug Development and Treatment
Tokyo Women's Medical University Journal, 2021 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019. It has been rapidly spreading worldwide ever since.
Fujiko Tsukahara, Yoshiro Maru
doaj +1 more source
Pharmaceutical Sciences and Research, 2020 Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid diseases.
Ana Khusnul Faizah +2 more
doaj +1 more source
Repurposing Existing Drugs for the Treatment of COVID-19
Annals of the American Thoracic Society, 2020 The rapid global spread and significant mortality associated with the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection has spurred an urgent race to find effective treatments. Repurposing existing drugs is a particularly attractive approach as pharmacokinetic and safety data already ...
Hugo Farne +5 more
openaire +4 more sources
Where are we with drug treatments for covid-19? [PDF]
BMJ, 2021 A year since the pandemic began, just a handful of lifesaving drugs have emerged as approved covid-19 treatments.
openaire +3 more sources
The Infectious Disease Ontology in the Age of COVID-19 [PDF]
, 2021 The Infectious Disease Ontology (IDO) is a suite of interoperable ontology modules that aims to provide coverage of all aspects of the infectious disease domain, including biomedical research, clinical care, and public health.
Babcock, Shane +3 more
core +1 more source
Therapeutic Development and Drugs for the Treatment of COVID-19 [PDF]
, 2020 SARS-CoV-2/novel coronavirus (2019-nCoV) is a new strain that has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India. The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020.
Maurya, Vimal K. +3 more
openaire +1 more source
Drug interactions of ivermectin with a focus on COVID-19 treatment
Muller Journal of Medical Sciences and Research, 2021 Treatment of COVID-19 largely depends on previously used drugs as there is no cure available coupled with shortage of effective vaccine with doubts about its long-term protection due to rapid viral mutations.
Padmaja Udaykumar +2 more
doaj +1 more source
Teicoplanin: an alternative drug for the treatment of COVID-19?
International Journal of Antimicrobial Agents, 2020 In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency.
Baron, Sophie Alexandra +4 more
openaire +4 more sources
Prevalence of Drug Resistance Pattern in Bacterial isolates of Endotracheal secretion from Ventilator Associated Pneumonia in COVID-19 Suspected Patients [PDF]
, 2023 Bacterial superinfections in ventilated COVID-19 patients has seen increase in mortality rates in COVID-19 pandemic. Hence, this study was designed to assess the presence of Drug resistant bacteria in COVID-19 suspected patients having symptoms of ...
Anamika Chalwadi, Sharvari Samant, Harapriya Kar, Krishna Suresh
core +2 more sources
Evaluation of drug-drug interactions and side effects in COVID-19 patients in an intensive care unit [PDF]
, 2022 BACKGROUND/AIM: Considering comorbidity rates in patients diagnosed with coronavirus disease 2019 (COVID-19), polypharmacy will be inevitable when the treatment for COVID-19 is added to the treatment of existing chronic disease conditions.
Erdoğan, Cem +3 more
core +1 more source